Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria

抗多重耐药细菌的广谱环状两亲肽的开发

• 批准号: 10481745
• 负责人: Assad Kazeminy
• 金额: $ 30万
• 依托单位: AJK BIOPHARMACEUTICAL LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-18 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10481745
• 关键词: Acinetobacter baumannii; Address; Adult; Amino Acids; Anti-Bacterial Agents; Antibiotics; Antimicrobial Resistance; Arginine; Bacteria; Bacterial Antibiotic Resistance; Bacterial Drug Resistance; Biological Assay; Body Weight; C57BL/6 Mouse; Carbapenems; Cations; Cell membrane; Centers for Disease Control and Prevention (U.S.); Cephalosporins; Charge; Cyclic Peptides; Daptomycin; Data; Development; Dose; Drug Kinetics; Drug resistance; Enterobacter; Enterococcus faecium; Erythrocytes; Escherichia coli; Eukaryotic Cell; Exhibits; Feasibility Studies; Government; Half-Life; Health Personnel; Hemolysis; Histology; Human; Hydrophobicity; In Vitro; Inbred BALB C Mice; Infection; Intravenous; Klebsiella pneumoniae; Lead; Legal patent; Levaquin; Libraries; Lipids; Maximum Tolerated Dose; Medical; Membrane; Methicillin; Microbial Biofilms; Modeling; Monitor; Multi-Drug Resistance; Multiple Bacterial Drug Resistance; Mus; Mycobacterium tuberculosis; Patients; Peptide Library; Peptides; Periodicity; Persons; Phase; Polymyxin B; Pseudomonas aeruginosa; Public Health; Pyrazinamide; Reporting; Resistance; Resistance development; Resort; Safety; Staphylococcus aureus; Staphylococcus aureus infection; Structure-Activity Relationship; Tetracyclines; Therapeutic Index; Time; Toxic effect; Tryptophan; United Kingdom; Vancomycin; Work; amphiphilicity; antimicrobial; antimicrobial drug; antimicrobial peptide; antimicrobial resistant infection; assay development; base; biological systems; clinically relevant; cohort; cytotoxicity; design; dosage; economic impact; efficacy study; experimental study; improved; in vivo; indexing; insight; isoniazid; lead optimization; methicillin resistant Staphylococcus aureus; mortality; mouse model; multi-drug resistant pathogen; novel; pathogen; pathogenic bacteria; peptide analog; phase 2 study; resistant strain

ABSTRACT The emergence of antibacterial resistance to common frontline antibiotics, such as methicillin, vancomycin, cephalosporins, and carbapenem, have created a global public health challenge for millions of patients. It is therefore critical to discover and commercialize new antimicrobial agents that can successfully neutralize multidrug-resistant bacteria (MDRB) with minimal toxicity. The objective of this proposal is to develop unique first-in-class amphiphilic cyclic antimicrobial peptides (AMPs) that are active against clinically relevant pathogens like Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species (ESKAPE pathogens). We propose to develop AMPs containing natural and/or unnatural hydrophobic and positively charged residues for their broad- spectrum activity and efficacy against specific MDR pathogens, using in vitro and in vivo assays. We have discovered that a cyclic amphipathic peptide [R4W4], which comprises tryptophan (W) and arginine (R) amino acids was effective against diverse bacterial pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) (MIC = 2.7 µg/mL), Pseudomonas aeruginosa (MIC = 42.8 µg/mL), Klebsiella pneumoniae (MIC = 16.0 µg/mL), and Escherichia coli (MIC = 16.0 µg/mL) and showed synergistic activity with tetracycline against MRSA, and isoniazid and pyrazinamide against Mycobacterium tuberculosis. Based on this template, we generated a new library of peptides (>200) with enhanced antimicrobial activities. For example, IFX-027, IFX-135, IFX-145, IFX-146, IFX-154, and IFX-301 showed MIC = 1.5-25 µg/mL against Gram+ve and Gram-ve bacteria. Several of the lead compounds demonstrated synergistic activity with several other antibiotics with fractional inhibitory concentration (FIC) indices ranging from 0.3-0.5. Our lead peptides (IFX- 031, IFX-031-1, and IFX-111) also reduced biofilm formation by MRSA and P. aeruginosa. IFX-301 was found to be nontoxic at a dose level of 50 mg/kg in mice, and all peptides were not toxic against human red blood cells (hRBC) (HC50>500 μg/mL). In Aim 1, we will establish a structure-activity relationship (SAR) based on the six lead peptides to obtain insights into the structural determinants responsible for the molecules’ selectivity towards bacterial pathogens. The most potent compounds will be further evaluated for their stability, cytotoxicity, and development over time to antimicrobial resistance. The proposed milestones for Aim 1 are to identify five lead peptide analogs with MIC ≤5 µg/mL and MIC ≤10 µg/mL respectively against Gram+ve and Gram-ve bacteria, and hRBC hemolysis of ≤5% at a concentration of 20 times the MIC value. In Aim 2, we will evaluate the in vivo efficacy and toxicity, preliminary pharmacokinetics (e.g., Cmax, tmax, t1/2), and efficacy of the 2-3 lead antimicrobial peptide analogs identified in Aim 1 on a murine infection model against four pathogenic bacteria. At the successful completion of Phase I, the most potent compound with a large therapeutic index will be advanced to Phase II studies and be the focus for an IND application.

抽象的 常见一线抗生素（如甲氧西林、万古霉素、头孢菌素）出现细菌耐药性， 和碳青霉烯类药物已给数百万患者带来了全球公共卫生挑战，因此发现和发现这一点至关重要。 将新型抗菌剂商业化，能够以最小的成本成功中和多重耐药细菌（MDRB） 该提案的目的是开发独特的一流两亲性环状抗菌肽（AMP）。 对临床相关病原体有活性，如屎肠球菌、金黄色葡萄球菌、克雷伯氏菌 肺炎链球菌、鲍曼不动杆菌、铜绿假单胞菌和肠杆菌属（ESKAPE 病原体）。 建议开发含有天然和/或非天然疏水性和带正电残基的 AMP，以实现其广泛的 我们通过体外和体内试验发现了针对特定 MDR 病原体的谱活性和功效。 环状两亲肽 [R4W4]，包含色氨酸 (W) 和精氨酸 (R) 氨基酸，可有效对抗 多种细菌病原体，例如耐甲氧西林金黄色葡萄球菌 (MRSA) (MIC = 2.7 µg/mL)， 铜绿假单胞菌 (MIC = 42.8 µg/mL)、肺炎克雷伯菌 (MIC = 16.0 µg/mL) 和大肠杆菌 (MIC = 16.0 µg/mL)，与四环素对 MRSA 具有协同活性，与异烟肼和吡嗪酰胺对 MRSA 具有协同活性 基于该模板，我们生成了一个具有增强功能的新肽库（>200）。 例如，IFX-027、IFX-135、IFX-145、IFX-146、IFX-154 和 IFX-301 显示 MIC = 1.5-25。 µg/mL 对革兰氏阳性菌和革兰氏阴性菌具有协同活性。 我们的先导肽 (IFX-) 的抑制浓度分数 (FIC) 指数范围为 0.3-0.5。 031、IFX-031-1 和 IFX-111）也能减少 MRSA 和铜绿假单胞菌生物膜的形成。 在小鼠中，剂量为 50 mg/kg 时无毒，并且所有肽对人红细胞 (hRBC) 均无毒性 (HC50>500 μg/mL) 在目标 1 中，我们将基于六种先导肽建立构效关系 (SAR)。 深入了解导致分子对细菌病原体选择性的结构决定因素。 最有效的化合物将进一步评估其稳定性、细胞毒性以及随着时间的推移抗菌剂的发展 目标 1 的拟议里程碑是鉴定 5 种 MIC ≤5 µg/mL 和 MIC ≤10 的先导肽类似物。 µg/mL 分别对抗 Gram+ve 和 Gram-ve 细菌，20 倍浓度下 hRBC 溶血≤5% 在目标 2 中，我们将评估体内功效和毒性、初步药代动力学（例如 Cmax、tmax、 t1/2），以及目标 1 中确定的 2-3 个先导抗菌肽类似物在小鼠感染模型上对四种药物的功效 在第一阶段成功完成后，具有大治疗指数的最有效的化合物将出现。 进入 II 期研究并成为 IND 申请的焦点。